Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria
| Autor: | Evaggelia Kampouropoulou, Aimilios Lallas, Elizabeth Lazaridou, Zoe Apalla, Theodoros Sidiropoulos, Marina Papageorgiou, Maria Smaragdi, Florentina Delli |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Allergy Time Factors Phases of clinical research Dermatology Omalizumab 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Refractory Recurrence Anti-Allergic Agents medicine Humans Chronic Urticaria Adverse effect Retrospective Studies Angioedema Greece business.industry Medical record Middle Aged medicine.disease Discontinuation Treatment Outcome 030228 respiratory system Withholding Treatment Female medicine.symptom business medicine.drug |
| Zdroj: | European journal of dermatology : EJD. 30(6) |
| ISSN: | 1952-4013 |
| Popis: | Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) not responding to antihistamines. Data on omalizumab use in real-world settings and in different populations are lacking. To record our five-year experience of omalizumab use in patients with refractory CSU in a real-world setting. A retrospective analysis of medical records of 80 patients with refractory CSU was performed. Demographic, and clinical characteristics, patterns of response, discontinuation strategies and rate of recurrence were analysed. Eighty individuals were included. UAS7 and DLQI significantly decreased from baseline. Complete response was achieved in 86.3%. Late response was observed at 27.5% of the patients. After discontinuation, 21.7% of patients reinitiated omalizumab due to relapse. The mean number of omalizumab administrations up to first discontinuation was 6.8 (based on an approach to shorten the treatment interval). Only 15.0% of patients experienced adverse events during treatment. Omalizumab, with long-term management, was highly effective and safe in achieving control of refractory CSU, with more favourable responses compared to Phase III clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink